|
1
|
Iki M: Epidemiology of osteoporosis in
Japan. Clin Calcium. 22:797–803. 2012.(In Japanese). PubMed/NCBI
|
|
2
|
Liberman UA, Weiss SR, Bröll J, Minne HW,
Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J,
Favus M, et al: The Alendronate Phase III Osteoporosis Treatment
Study Group: Effect of oral alendronate on bone mineral density and
the incidence of fractures in postmenopausal osteoporosis. N Engl J
Med. 333:1437–1443. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis
A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ,
Pinkas H and Wang KK: Esophagitis associated with the use of
alendronate. N Engl J Med. 335:1016–1021. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Graham DY, Malaty HM and Goodgame R:
Primary amino-bisphosphonates: A new class of gastrotoxic drugs -
comparison of alendronate and aspirin. Am J Gastroenterol.
92:1322–1325. 1997.PubMed/NCBI
|
|
5
|
Yoshimura N, Muraki S, Oka H, Kawaguchi H,
Nakamura K and Akune T: Cohort profile: Research on
osteoarthritis/osteoporosis against disability study. Int J
Epidemiol. 39:988–995. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagasue T, Nakamura S, Kochi S, Kurahara
K, Yaita H, Kawasaki K and Fuchigami T: Time trends of the impact
of Helicobacter pylori infection and nonsteroidal
anti-inflammatory drugs on peptic ulcer bleeding in Japanese
patients. Digestion. 91:37–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kinoshita Y, Kawanami C, Kishi K, Nakata
H, Seino Y and Chiba T: Helicobacter pylori independent
chronological change in gastric acid secretion in the Japanese.
Gut. 41:452–458. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fujiwara Y and Arakawa T: Epidemiology and
clinical characteristics of GERD in the Japanese population. J
Gastroenterol. 44:518–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malfertheiner P, Fass R, Quigley EM,
Modlin IM, Malagelada JR, Moss SF, Holtmann G, Goh KL, Katelaris P,
Stanghellini V, et al: Review article: From gastrin to
gastro-oesophageal reflux disease - a century of acid suppression.
Aliment Pharmacol Ther. 23:683–690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abrahamsen B, Eiken P and Eastell R:
Proton pump inhibitor use and the antifracture efficacy of
alendronate. Arch Intern Med. 171:998–1004. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orimo H, Hayashi Y, Fukunaga M, Sone T,
Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J,
et al: Osteoporosis Diagnostic Criteria Review Committee: Japanese
Society for Bone and Mineral Research: Diagnostic criteria for
primary osteoporosis: Year 2000 revision. J Bone Miner Metab.
19:331–337. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lundell LR, Dent J, Bennett JR, Blum AL,
Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler
SJ, et al: Endoscopic assessment of oesophagitis: Clinical and
functional correlates and further validation of the Los Angeles
classification. Gut. 45:172–180. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kusano M, Shimoyama Y, Sugimoto S,
Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H,
Ino K, et al: Development and evaluation of FSSG: Frequency scale
for the symptoms of GERD. J Gastroenterol. 39:888–891. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shiraki M, Kushida K, Fukunaga M,
Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T,
Morii H, et al: The Alendronate Phase III Osteoporosis Treatment
Research Group: A double-masked multicenter comparative study
between alendronate and alfacalcidol in Japanese patients with
osteoporosis. Osteoporos Int. 10:183–192. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Uchida S, Taniguchi T, Shimizu T, Kakikawa
T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki
M, et al: Therapeutic effects of alendronate 35 mg once weekly and
5 mg once daily in Japanese patients with osteoporosis: A
double-blind, randomized study. J Bone Miner Metab. 23:382–388.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sipponen P and Härkönen M: Hypochlorhydric
stomach: A risk condition for calcium malabsorption and
osteoporosis? Scand J Gastroenterol. 45:133–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang YX, Lewis JD, Epstein S and Metz DC:
Long-term proton pump inhibitor therapy and risk of hip fracture.
JAMA. 296:2947–2953. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaye JA and Jick H: Proton pump inhibitor
use and risk of hip fractures in patients without major risk
factors. Pharmacotherapy. 28:951–959. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Penning-van Beest FJ, Goettsch WG, Erkens
JA and Herings RM: Determinants of persistence with
bisphosphonates: A study in women with postmenopausal osteoporosis.
Clin Ther. 28:236–242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tuukkanen J and Väänänen HK: Omeprazole, a
specific inhibitor of H+-K+-ATPase, inhibits bone resorption in
vitro. Calcif Tissue Int. 38:123–125. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mattsson JP, Väänänen K, Wallmark B and
Lorentzon P: Omeprazole and bafilomycin, two proton pump
inhibitors: Differentiation of their effects on gastric, kidney and
bone H(+)-translocating ATPases. Biochim Biophys Acta.
1065:261–268. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gertz BJ, Holland SD, Kline WF,
Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC and
Porras AG: Studies of the oral bioavailability of alendronate. Clin
Pharmacol Ther. 58:288–298. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Itoh S, Sekino Y, Shinomiya K and Takeda
S: The effects of risedronate administered in combination with a
proton pump inhibitor for the treatment of osteoporosis. J Bone
Miner Metab. 31:206–211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Orimo H, Shiraki M, Hayashi Y, Hoshino T,
Onaya T, Miyazaki S, Kurosawa H, Nakamura T and Ogawa N: Effects of
1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and
vertebral fractures in patients with postmenopausal osteoporosis.
Calcif Tissue Int. 54:370–376. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shikari M, Kushida K, Yamazaki K, Nagai T,
Inoue T and Orimo H: Effects of 2 years' treatment of osteoporosis
with 1 alpha-hydroxy vitamin D3 on bone mineral density and
incidence of fracture: A placebo-controlled, double-blind
prospective study. Endocr J. 43:211–220. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshimura M, Nagahara A, Ohtaka K, Shimada
Y, Asaoka D, Kurosawa A, Osada T, Kawabe M, Hojo M, Yoshizawa T, et
al: Presence of vertebral fractures is highly associated with
hiatal hernia and reflux esophagitis in Japanese elderly people.
Intern Med. 47:1451–1455. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamaguchi T, Sugimoto T, Yamada H, Kanzawa
M, Yano S, Yamauchi M and Chihara K: The presence and severity of
vertebral fractures is associated with the presence of esophageal
hiatal hernia in postmenopausal women. Osteoporos Int. 13:331–336.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miyakoshi N, Kasukawa Y, Sasaki H, Kamo K
and Shimada Y: Impact of spinal kyphosis on gastroesophageal reflux
disease symptoms in patients with osteoporosis. Osteoporos Int.
20:1193–1198. 2009. View Article : Google Scholar : PubMed/NCBI
|
